Sarepta Therapeutics (SRPT) EBT Margin: 2012-2025
Historic EBT Margin for Sarepta Therapeutics (SRPT) over the last 11 years, with Jun 2025 value amounting to -62.76%.
- Sarepta Therapeutics' EBT Margin fell 6650.00% to -62.76% in Q2 2025 from the same period last year, while for Jun 2025 it was -8.88%, marking a year-over-year decrease of 1302.00%. This contributed to the annual value of 13.71% for FY2024, which is 5554.00% up from last year.
- According to the latest figures from Q2 2025, Sarepta Therapeutics' EBT Margin is -62.76%, which was down 340.60% from 26.08% recorded in Q4 2024.
- In the past 5 years, Sarepta Therapeutics' EBT Margin registered a high of 26.08% during Q4 2024, and its lowest value of -202.25% during Q1 2023.
- Moreover, its 3-year median value for EBT Margin was 3.74% (2024), whereas its average is -24.81%.
- In the last 5 years, Sarepta Therapeutics' EBT Margin slumped by 15,285bps in 2023 and then skyrocketed by 21,228bps in 2024.
- Quarterly analysis of 5 years shows Sarepta Therapeutics' EBT Margin stood at -60.50% in 2021, then skyrocketed by 2,130bps to -39.20% in 2022, then skyrocketed by 4,938bps to 10.17% in 2023, then soared by 1,591bps to 26.08% in 2024, then tumbled by 6,650bps to -62.76% in 2025.
- Its last three reported values are -62.76% in Q2 2025, 26.08% for Q4 2024, and 7.28% during Q3 2024.